Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of combining temozolomide and thalidomide in treating patients who have recurrent or progressive brain tumor.
Key facts
- Study ID
- NCT00006358
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 44
- Starts
- 2000-06-13
- Expected to finish
- 2006-07-20
- Last updated by the study team
- 2018-06-26
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
- UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
- Neuro-Oncology Branch — Bethesda, Maryland, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
- Simmons Cancer Center - Dallas — Dallas, Texas, United States
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
- University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.